1:55 PM
 | 
Feb 05, 2018
 |  BC Extra  |  Clinical News

Shield falls on Phase III Feraccru miss

Shield Therapeutics plc (LSE:STX) fell 65p (58%) to 47.50p on Monday after reporting that Feraccru ferric maltol missed the primary endpoint in the U.S. Phase III AEGIS-CKD trial to treat iron deficiency anemia (IDA) in patients with non-dialysis-dependent chronic kidney disease (CKD).

On the 168-patient...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >